As Adamas Pharmaceuticals (ADMS) Market Value Declined, Shareholder Granite Point Capital Management LP Has Cut by $2.08 Million Its Position; Teleflex (TFX) Market Value Rose While Mackay Shields Has Decreased Position by $9.99 Million

April 21, 2018 - By Peter Erickson

Teleflex Incorporated (NYSE:TFX) Logo

Warren Lammert decreased its stake in Adamas Pharmaceuticals Inc (ADMS) by 18.89% based on its latest 2017Q4 regulatory filing with the SEC. Granite Point Capital Management Lp sold 63,000 shares as the company’s stock declined 31.02% with the market. The hedge fund run by Warren Lammert held 270,515 shares of the health care company at the end of 2017Q4, valued at $9.17M, down from 333,515 at the end of the previous reported quarter. Granite Point Capital Management Lp who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be less bullish one the $753.01 million market cap company. The stock increased 1.52% or $0.42 during the last trading session, reaching $28.09. About 877,843 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since April 21, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.

Mackay Shields Llc decreased its stake in Teleflex Inc (TFX) by 32.89% based on its latest 2017Q4 regulatory filing with the SEC. Mackay Shields Llc sold 40,296 shares as the company’s stock rose 3.29% while stock markets declined. The institutional investor held 82,214 shares of the medical and dental instruments company at the end of 2017Q4, valued at $20.46M, down from 122,510 at the end of the previous reported quarter. Mackay Shields Llc who had been investing in Teleflex Inc for a number of months, seems to be less bullish one the $12.31B market cap company. The stock increased 0.52% or $1.39 during the last trading session, reaching $271.03. About 241,946 shares traded. Teleflex Incorporated (NYSE:TFX) has risen 32.04% since April 21, 2017 and is uptrending. It has outperformed by 20.49% the S&P500.

Since January 2, 2018, it had 0 insider buys, and 12 insider sales for $9.79 million activity. Deren John sold $347,449 worth of stock. SMITH BENSON also sold $2.43M worth of Teleflex Incorporated (NYSE:TFX) shares. Klasko Stephen K. M.D. sold $55,288 worth of stock or 200 shares.

Investors sentiment increased to 1.13 in 2017 Q4. Its up 0.03, from 1.1 in 2017Q3. It is positive, as 19 investors sold TFX shares while 132 reduced holdings. 62 funds opened positions while 108 raised stakes. 39.40 million shares or 0.28% more from 39.29 million shares in 2017Q3 were reported. Scout Investments holds 58,811 shares. Segall Bryant Hamill Ltd Liability has 2,008 shares. Eaton Vance Mngmt holds 0.04% or 58,367 shares. Moreover, Stratos Wealth Prtn Limited has 0% invested in Teleflex Incorporated (NYSE:TFX). 10,700 are owned by Alpine Woods Capital Invsts Llc. Legal And General Public Limited Company accumulated 89,889 shares or 0.02% of the stock. First Quadrant Ltd Partnership Ca holds 0.14% of its portfolio in Teleflex Incorporated (NYSE:TFX) for 30,138 shares. Moreover, Proshare Advsr Ltd Liability Corp has 0.01% invested in Teleflex Incorporated (NYSE:TFX) for 5,122 shares. Fred Alger Management reported 5,000 shares stake. Hemenway Trust Co Llc, New Hampshire-based fund reported 1,200 shares. Legacy Private Trust Company owns 2,805 shares. Evercore Wealth Ltd Liability Corporation accumulated 3,075 shares or 0.03% of the stock. Advisor Prtn Lc has invested 0.05% of its portfolio in Teleflex Incorporated (NYSE:TFX). Texas Permanent School Fund holds 30,452 shares or 0.09% of its portfolio. Moreover, Whittier Tru Com has 0% invested in Teleflex Incorporated (NYSE:TFX) for 150 shares.

Mackay Shields Llc, which manages about $81.03B and $2.74B US Long portfolio, upped its stake in Xpo Logistics Inc (NYSE:XPO) by 397,786 shares to 407,902 shares, valued at $37.36M in 2017Q4, according to the filing. It also increased its holding in Wright Med Group Inc (Prn) by 5.31M shares in the quarter, for a total of 6.85 million shares, and has risen its stake in Becton Dickinson & Co.

Analysts await Teleflex Incorporated (NYSE:TFX) to report earnings on May, 3. They expect $1.94 EPS, up 7.78% or $0.14 from last year’s $1.8 per share. TFX’s profit will be $88.14M for 34.93 P/E if the $1.94 EPS becomes a reality. After $2.44 actual EPS reported by Teleflex Incorporated for the previous quarter, Wall Street now forecasts -20.49% negative EPS growth.

Among 12 analysts covering Teleflex (NYSE:TFX), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. Teleflex had 35 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating by KeyBanc Capital Markets given on Tuesday, September 5. The rating was maintained by Brean Capital with “Buy” on Friday, February 26. Needham initiated it with “Buy” rating and $221 target in Tuesday, March 7 report. The stock of Teleflex Incorporated (NYSE:TFX) has “Hold” rating given on Thursday, June 8 by Leerink Swann. Needham maintained the stock with “Buy” rating in Friday, November 3 report. The firm has “Overweight” rating by Piper Jaffray given on Monday, November 30. Brean Capital maintained Teleflex Incorporated (NYSE:TFX) rating on Friday, July 31. Brean Capital has “Buy” rating and $145 target. Jefferies maintained Teleflex Incorporated (NYSE:TFX) on Thursday, February 22 with “Buy” rating. Needham maintained Teleflex Incorporated (NYSE:TFX) on Friday, August 4 with “Buy” rating. The firm earned “Strong Buy” rating on Wednesday, January 6 by Raymond James.

Granite Point Capital Management Lp, which manages about $1.02 billion US Long portfolio, upped its stake in Axon Enterprise Inc by 30,000 shares to 81,200 shares, valued at $2.15M in 2017Q4, according to the filing. It also increased its holding in Axt Inc (NASDAQ:AXTI) by 130,000 shares in the quarter, for a total of 172,000 shares, and has risen its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX).

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on May, 8. They expect $-1.38 EPS, down 91.67% or $0.66 from last year’s $-0.72 per share. After $-1.27 actual EPS reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 8.66% negative EPS growth.

Among 13 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Adamas Pharmaceuticals had 36 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Thursday, February 22 with “Buy”. On Tuesday, January 19 the stock rating was initiated by Mizuho with “Neutral”. The rating was maintained by Piper Jaffray with “Buy” on Thursday, August 31. The firm has “Buy” rating given on Thursday, September 8 by Mizuho. Aegis Capital initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, September 22. Aegis Capital has “Buy” rating and $29 target. As per Thursday, May 12, the company rating was maintained by Mizuho. The rating was maintained by Noble Financial on Wednesday, August 9 with “Buy”. Zacks downgraded Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, August 7 to “Buy” rating. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, October 3 by Piper Jaffray. Leerink Swann initiated the stock with “Buy” rating in Wednesday, April 4 report.

Teleflex Incorporated (NYSE:TFX) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>